TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
A Single-center Randomized Controlled Clinical Trial of TACE Combined With Anlotinib Comparing With TACE in the Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Guoliang Shao
- Phone Number: +8613958183472
- Email: shaoguoliang666@hotmail.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Zhejiang Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has no contraindication to chemotherapy, and has no obvious obstacles in the function of major organs such as heart, lung, liver and kidney;
- Subject has middle-advanced liver cancer of Barcelona Clinic Liver Cancer stages B/C ;
- Liver function child-pugh class A or B; Karnofsky (KPS) score > 60 points;
- Subject could not accept surgical resection or refuse surgical operation;and who did not receive other treatment before operation.
5.18~75 years old; ECOG PS score: 0-1 points; expected survival period is more than 3 months.
Exclusion Criteria:
- Subject has contraindications to chemotherapy;
- Subject has obstacle in the function of major organs such as heart, lung, liver and kidney;
- Severe coagulation dysfunction (prothrombin time > 18 s or hemorrhagic tendency);
- Uncontrollable hypertension and portal hypertension;
- Hepatic artery-portal vein or hepatic vein fistula or portal vein trunk cancer thrombus;
- A large amount of ascites or refractory ascites;
- With distant metastasis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: TACE group
Device: Transcatheter arterial chemoembolization(TACE)
|
The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography.
The location, morphology and blood supply of liver tissue lesions were comprehensively understood.
The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation.
The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation.
The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization.
Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation.
Until the disease progresses.
|
|
Experimental: TACE+Anlotinib group
Device: Transcatheter arterial chemoembolization Drug: Anlotinib Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
|
The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography.
The location, morphology and blood supply of liver tissue lesions were comprehensively understood.
The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation.
The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation.
The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization.
Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation.
Until the disease progresses.
Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PFS
Time Frame: 12 months
|
Progress Free Survival
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guoliang Shao, Zhejiang Cancer Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ALTNZJ-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.